Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences

American Journal of Surgical Pathology

Volumn 31, Issue 12, 2007, Pages 1825-1833

  Mohammed, Rabab A A ^a   Martin, Stewart G ^a   Gill, Muhammad S ^a   Green, Andrew R ^b   Paish, Emma C ^a   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Breast cancer; Lymphovascular invasion; Podoplanin and prognosis

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; PODOPLANIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; DISEASE FREE INTERVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTIGENS, CD34; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 36448974934     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31806841f6     Document Type: Article

References (44)

1. Arigami T, Natsugoe S, Uenosono Y, et al. Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer. 2005;93:688-693.
2. Balslev I, Axelsson CK, Zedeler K, et al. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat. 1994;32:281-290.
3. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
4. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-533.
5. Eden P, Ritz C, Rose C, et al. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004;40:1837-1841.
6. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20:479-489.
7. Ellis IO, Coleman D, Wells C, et al. Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol. 2006;59:138-145.
8. Evangelou E, Kyzas PA, Trikalinos TA. Comparison of the diagnostic accuracy of lymphatic endothelium markers: bayesian approach. Mod Pathol. 2005;18:1490-1497.
9. Fiedler U, Christian S, Koidl S, et al. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol. 2006;168:1045-1053.
10. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-nodenegative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364:858-868.
11. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
12. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230:692-696.
13. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-219.
14. Gasparini G, Meli S, Panizzoni GA, et al. Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat. 1992;20:195-204.
15. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
16. Gonzalez-Vela MC, Garijo MF, Fernandez FA, et al. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract. 1999;195:611-618.
17. Hong YK, Detmar M. Prox1, master regulator of the lymphatic vasculature phenotype. Cell Tissue Res. 2003;314:85-92.
18. Kaiserling E. Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology. Pathologe. 2004;25:362-374.
19. Kato T, Kameoka S, Kimura T, et al. Blood vessel invasion as a predictor of long-term survival for Japanese patients with breast cancer. Breast Cancer Res Treat. 2002;73:1-12.
20. Kuru B, Camlibel M, Gulcelik MA, et al. Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas. J Surg Oncol. 2003;83:167-172.
21. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995;76:1772-1778.
22. Lee AH, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006;42:357-362.
23. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Importance of lymph vessels in gastric cancer: a prognostic indicator in general and a predictor for lymph node metastasis in early stage cancer. J Clin Pathol. 2006;59:77-82.
24. Niakosari F, Kahn HJ, Marks A, et al. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol. 2005;141:440-444.
25. Obermair A, Kurz C, Czerwenka K, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer. 1995;62:126-131.
26. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448-456.
27. Pepper MS, Tille JC, Nisato R, et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314:167-177.
28. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994;24:41-47.
29. Podgrabinska S, Braun P, Velasco P, et al. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA. 2002;99:16069-16074.
30. Pusztaszeri M, Chaubert P, Seelentag W, et al. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2005;54:385-395.
31. Quek ML, Stein JP, Nichols PW, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174:103-106.
32. RayChaudhury A, Elkins M, Kozien D, et al. Regulation of PECAM-1 in endothelial cells during cell growth and migration. Exp Biol Med (Maywood). 2001;226:686-691.
33. Romer LH, McLean NV, Yan HC, et al. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol. 1995;154:6582-6592.
34. Sakuragi N, Takeda N, Hareyama H, et al. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma. Cancer. 2000;88:2578-2583.
35. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-921.
36. Schoppmann SF, Birner P, Studer P, et al. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res. 2001;21:2351-2355.
37. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240:306-312.
38. Truong PT, Yong CM, Abnousi F, et al. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg. 2005;200:912-921.
39. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006;94:1643-1649.
40. Vieira SC, Silva BB, Pinto GA, et al. CD34 as a marker for evaluating angiogenesis in cervical cancer. Pathol Res Pract. 2005;201:313-318.
41. Wobser M, Siedel C, Schrama D, et al. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch Dermatol Res. 2006;297:352-357.
42. Wong JS, O'Neill A, Recht A, et al. The relationship between lymphatic vessel invasion, tumor size, and pathologic nodal status: can we predict who can avoid a third field in the absence of axillary dissection? Int J Radiat Oncol Biol Phys. 2000;48:133-137.
43. Woo CS, Silberman H, Nakamura SK, et al. Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg. 2002;184:337-340.
44. Zehnder JL, Hirai K, Shatsky M, et al. The cell adhesion molecule CD31 is phosphorylated after cell activation. Down-regulation of CD31 in activated T lymphocytes. J Biol Chem. 1992;267:5243-5249.